Eli Lilly and Company (NYSE:LLY) PT Raised to $850.00 at Truist Financial

Eli Lilly and Company (NYSE:LLYFree Report) had its target price increased by Truist Financial from $650.00 to $850.00 in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Wells Fargo & Company raised their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a research note on Tuesday. BMO Capital Markets raised their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an outperform rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft began coverage on Eli Lilly and Company in a report on Thursday, November 9th. They set a hold rating and a $535.00 price objective on the stock. TheStreet lowered Eli Lilly and Company from a b rating to a c+ rating in a report on Monday, December 4th. Finally, StockNews.com raised Eli Lilly and Company from a hold rating to a buy rating in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of Moderate Buy and an average target price of $621.81.

Read Our Latest Stock Report on LLY

Eli Lilly and Company Stock Up 0.6 %

Shares of Eli Lilly and Company stock opened at $740.16 on Wednesday. Eli Lilly and Company has a 1 year low of $309.20 and a 1 year high of $745.70. The stock has a 50-day moving average price of $620.02 and a 200 day moving average price of $580.17. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. The company has a market cap of $702.64 billion, a P/E ratio of 127.61, a P/E/G ratio of 2.06 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 50.78% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period last year, the business earned $2.09 EPS. The business’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 12.6 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 77.93%.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 1,180 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $645.60, for a total transaction of $761,808.00. Following the sale, the insider now owns 99,542,630 shares of the company’s stock, valued at approximately $64,264,721,928. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 195,055 shares of company stock valued at $125,254,657. 0.13% of the stock is owned by corporate insiders.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently modified their holdings of the company. Buckhead Capital Management LLC lifted its position in shares of Eli Lilly and Company by 0.7% during the 4th quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock worth $1,226,000 after buying an additional 15 shares during the period. Levin Capital Strategies L.P. lifted its position in shares of Eli Lilly and Company by 3.8% during the 4th quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock worth $242,000 after buying an additional 15 shares during the period. Clearwater Capital Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.3% during the 4th quarter. Clearwater Capital Advisors LLC now owns 1,202 shares of the company’s stock worth $701,000 after buying an additional 15 shares during the period. JGP Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares during the period. Finally, Cassia Capital Partners LLC lifted its position in shares of Eli Lilly and Company by 1.8% during the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after buying an additional 17 shares during the period. Institutional investors and hedge funds own 81.38% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.